Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Molly Shotts

Brooklyn, NY Physician Assistant

NPI 1376103895 CMS profile 11254233

1414 Newkirk Ave, Brooklyn, NY 11226

Open in the dashboard

General payments

$2,585

72 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Molly Shotts of Brooklyn, NY is reported in the CMS Open Payments database as having received $2,585 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $50 2
2023 General $547 9
2022 General $487 11
2021 General $1,502 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Molly Shotts
  • New York median
  • Middle half of New York
  • National median

In program year 2025, general payments to Molly Shotts were reported at $0. Among 69,423 New York profiles paid that year, the median was $180 and the middle half received between $58 and $640.

Show as a table
Year Molly Shotts New York median Middle half National median
2019 $0 $175 $53–$665 $163
2020 $0 $122 $37–$426 $114
2021 $1,502 $144 $44–$514 $132
2022 $487 $160 $51–$578 $149
2023 $547 $170 $54–$593 $160
2024 $50 $173 $56–$618 $164
2025 $0 $180 $58–$640 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Nevro Corp. $1,056 12 payments
  2. Boston Scientific Corporation $437 6 payments
  3. AbbVie, Inc. $316 16 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $253 16 payments
  5. Medtronic, Inc. $166 2 payments
  6. Collegium Pharmaceutical, Inc. $89 5 payments
  7. RedHill Biopharma Inc. $48 3 payments
  8. Allergan Inc. $44 2 payments
  9. Horizon Therapeutics plc $43 2 payments
  10. Novartis Pharmaceuticals Corporation $31 2 payments
  11. Other $102 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $2,585 72 payments
Products named General payments · program years 2021–2024
  1. Omnia $721 8 payments
  2. Senza $335 4 payments
  3. RELISTOR $253 16 payments
  4. UBRELVY $183 9 payments
  5. VECTRIS $166 2 payments
  6. WAVEWRITER ALPHA $157 2 payments
  7. WaveWriter Alpha Prime 16 $125 2 payments
  8. BOTOX $114 5 payments
  9. XTAMPZA $89 5 payments
  10. Movantik $48 3 payments
  11. Other $310 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record